Modification of the course of post-COVID syndrome associated with reactivation of chronic persistent Epstein−Barr virus infection and chronic nasopharyngotonsillitis of mixed etiology

Cover Page


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

A wide range of symptoms that occur in patients with post-COVID syndrome can include both manifestations of the clinical consequences of COVID-19 and symptoms of an exacerbation of a chronic pathology that they had before the development of coronavirus infection. Correct assessment of clinical data can help determine the origin of the existing manifestations of the disease and build a plan for adequate diagnostic and therapeutic measures.

In the article, on the example of a clinical case, a variant of the modified (exacerbation of chronic pathology) course of the post-COVID syndrome was analyzed. An example of modern laboratory diagnostics of reactivation of chronic persistent Epstein–Barr virus infection and exacerbation of chronic nasopharyngotonsillitis of mixed viral-bacterial-mycotic etiology, developed against the background of post-COVID syndrome, is given. The principles of therapy for this comorbid condition are presented and explained.

Full Text

Restricted Access

About the authors

Vladimir A. Neverov

North-Western State Medical University named after I.I. Mechnikov

Author for correspondence.
Email: v.neveroff@mail.ru
ORCID iD: 0009-0003-7951-5508
SPIN-code: 1798-2618

MD, Cand. Sci. (Med.), Assistant Professor

Russian Federation, Saint Petersburg

References

  1. Belotserkovskaya YuG, Romanovskikh AG, Smirnov IP, et al. Long COVID-19. Consilium Medicum. 2021;23(3):261–268. (In Russ.). doi: 10.26442/20751753.2021.3.200805
  2. Khasanova DR, Zhitkova YuV, Vaskaeva GR. Postcovid syndrome: a review of knowledge about the pathogenesis, neuropsychiatric manifestations and treatment prospects. Neurology, neuropsychiatry, psychosomatics. 2021;13(3):93–98. (In Russ.). doi: 10.14412/2074-27112021-3-93-98
  3. Amirov NB, Davletshina EI, Vasilyeva AG, Fatykhov RG. Postcovid syndrome: multisystem “deficiencies”. Bulletin of modern clinical medicine. 2021;14(6):94–104. (In Russ.). doi: 10.20969/VSKM.2021.14(6).94-104
  4. Metodicheskie rekomendatsii “Osobennosti techeniya long-COVID infektsii. Terapevticheskie i reabilitatsionnye meropriyatiya”. 217 p. [Internet]. Available from: https://irk-gb6.ru/images/uploads/c0c122cdc473c3b9968cce024a0ccdac.pdf. Accessed: 02.09.2023. (In Russ.)
  5. COVID-19 rapid guideline: managing the long-term effects of COVID-19 [Internet]. Available from: https://www.nice.org.uk/guidance/ng188. Accessed: 31.08.2021.
  6. Diaz JV, Soriano JB. A Delphi consensus to advance on a clinical case definition for post COVID-19 condition: a WHO protocol. Protocol Exchange. 2021. doi: 10.21203/rs.3.pex-1480/v1
  7. Kabi A, Mohanty A, Mohanty AP, Kumar S. Post COVID-19 syndrome: a literature review. JAMMR. 2020;32(24):289–295. DOI: 0.9734/jammr/2020/v32i2430781
  8. Nalbandian A, Sehgal K, Gupta A, et al. Post-acute COVID-19 syndrome. Nat Med. 2021;27(4):601–615. doi: 10.1038/s41591-021-01283-z
  9. Perrin R, Riste L, Hann M, et al. Into the looking glass: Post-viral syndrome post COVID-19. Med hypotheses. 2020;144:110055. doi: 10.1016/j.mehy.2020.110055
  10. Long COVID or Post-COVID Conditions. CDC, 2021 [Internet]. Available from: https://www.cdc.gov/coronavirus/2019-ncov/long-term-effects/index.html. Accessed: 18.07.2021.
  11. van Kampen JJA, van de Vijver DAMC, Fraaij PLA et al. Duration and key determinants of infectious virus shedding in hospitalized patients with coronavirus disease-2019 (COVID-19). Nat. Commun. 2021. Vol. 267, No. 12. P. 1–6. doi: 10.1038/s41467-020-20568-4
  12. Marx V. Scientists set out to connect the dots on long COVID. Nat Methods. 2021;18(5):449–453. doi: 10.1038/s41592-021-01145-z13
  13. Avanzato VA, Matson MJ, Seifert SN, et al. Case study: Prolonged infectious SARS-CoV-2 shedding from an asymptomatic immunocompromised cancer patient. Cell. 2020;183(7):1901–1912. doi: 10.1016/j.cell.2020.10.049
  14. Choi B, Choudhary MC, Regan J, et al. Persistence and evolution of SARS-CoV-2 in an immunocompromised host. N Engl J Med. 2020;383(22):2291–2293. doi: 10.1056/NEJMc2031364
  15. Nagasaki Y, Kadowaki M, Nakamura A, et al. A case of a malignant lymphoma patient persistently infected with SARS-CoV-2 for more than 6 months. Medicina (Kaunas). 2023;59(1):108. doi: 10.3390/medicina59010108
  16. Camprubí D, Gaya A, Marcos MA, et al. Persistent replication of SARS-CoV-2 in a severely immunocompromised patient treated with several courses of remdesivir. Int J Infect Dis. 2021;104:379–381. doi: 10.1016/j.ijid.2020.12.050
  17. Helleberg M, Niemann CU, Moestrup KS, et al. Persistent COVID-19 in an immunocompromised patient temporarily responsive to two courses of remdesivir therapy. J Infect Dis. 2020;222(7):1103–1107. doi: 10.1093/infdis/jiaa446
  18. Moore JL, Ganapathiraju PV, Kurtz CP, Wainscoat B. A 63-year-old woman with a history of non-hodgkin lymphoma with persistent SARS-CoV-2 infection who was seronegative and treated with convalescent plasma. Am J Case Rep. 2020;21:e927812. doi: 10.12659/AJCR.927812
  19. Tenforde MW, Kim SS, Lindsell CJ, et al. Symptom duration and risk factors for delayed return to usual health among outpatients with COVID-19 in a multistate health care systems network – United States, March–June 2020. MMWR Morb Mortal Wkly Rep. 2020;69(30):993–998. doi: 10.15585/mmwr.mm6930e1

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2023 Eco-Vector


СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77 - 70763 от 21.08.2017 г.